

EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____
I hereby certify that, on the date indicated above, this paper
or fee was deposited with the U.S. Postal Service & that it
was addressed for delivery to the Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail
Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.: **07278**

Docket No.: 03940/100K485-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniela GUTMAN et al.

Serial No.: TBA

Confirmation No.: TBA

Filed: Concurrently Herewith

For: METHOD AND REAGENTS FOR N-ALKYLATING UREIDES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a
copy of Form PTO/SB/08A. Copies of the documents were filed during prosecution

of the parent application Serial No. 10/073,051.

The Form PTO/SB/08A lists a reissue application (U.S. Serial No. 375,340) for U.S. Patent No. 6,093,820 filed February 27, 2003.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08A) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO/SB/08A next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art

consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'JP 11', is written over a horizontal line.

Jay P. Lessler
Registration No. 41,151
Attorney for Applicant(s)

Dated: October 16, 2003

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Daniela Gutman
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	03940/100K485-US4

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	10/375,340	-	Gutman et al.	
	2	4,628,056	12/1986	Levitt et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	3	02/07729	01/31/02			
	4	2622981	12/1977			
	5	4028040	3/1992			
	6	726252	01/31/96			
	7	1939787	02/19/70			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	8	Thacker et al., "A Method for Determination of 5,5 Diphenylbarbituric Acid and Separation from 1,3 Dimethoxymethyl 5,5 Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography," Journal of Chromatography B, 710:149 155 (1998).		
	9	Raines, et al., "Conversion of Dimethoxymethyl Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog," The FASEB J., 13(4):A475, Ansract 394.2 (1999).		
	10	Raines, et al., "Conversion of Dimethoxymethyl Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Rat," The FASEB J., 10:A 155, Abstract 895 (1996).		
	11	Raines, et al., "Serum and Brain Levels of 5 5 Diphenylbarbituric Acid (DPB) After Administration of dimethoxymethyl Diphenylbarbituric Acid (DMMDPB) in the Rat," Epilepsia, 37:Supp. 5, p. 23, Abstract 1.84 (1996).		
	12	Raines, et al., "Differential Selectivity of Several Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse," Epilepsia, 20:105 113 (1979).		
	13	Raines, et al., "The Effects of 5,5 Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation Between Plasma and Brain Concentrations and Anticonvulsant Activity," Epilepsia, 16:575 581 (1975).		
	14	Raines, et al., "A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse," Journal of Pharmacology and Experimental Therapeutics, 186:315 322 (1973).		

W:1039 401100k	Date Considered
-------------------	--------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Daniela Gutman
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	03940/100K485-US4

15	The Merck Index, 10th Ed., 1983, p. 544 (entry 3697).	
16	Susumu Kamata, Nobuhiro Haga, Takeaki Matsui and Wataru Nagata, "Studies of Antitumor-Active 5-Fluorouracil Derivatives. I. Synthesis of N-Phthalidyl 5-Fluorouracil Derivatives", Chemical And Pharmaceutical Bulletin, Vol. 33, No. 8, 1985, pp. 3160-3175.	
17	J.P. Gesson, JC Jacquesy, D. Rambaud, "A practical method for N-alkylation of succinimide and glutarimide", Bulletin De La Societe Chimique De France, Vol. 129, No. 3, 1992, pp. 227-231.	
18	P. Casara et al., "Synthesis of acid stable fluorinated acylnucleosides", Vol. 32, No. 31, 1991, pp. 3823-3826.	
19	Foye, "Principles of Medicinal Chemistry", 3rd ed., 1990, pp. 164, 179.	
20	Karger et al., "Methoxymethyl Methanesulfonate, A Novel Active Oxyalkylating Agent", Journal of the American Chemical Society, 91:5663 (1969).	
21	Aldrich Chemical Catalog, 1990-1991, p. 303.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

{W:\039 401100k	Date Considered	
--------------------	--------------------	--